A Phase 4 interventional study of ranibizumab in Wet Age Related Macular Degeneration, sponsored by Novartis Pharmaceuticals. Completed at 101 sites in Italy. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2019-07-19.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 125 studies testing ranibizumab in Macular Degeneration — 3 open to participants now, 6 under way, 4 of them phase 3. Ranibizumab · Macular Degeneration.
Among the 125 studies testing ranibizumab in Macular Degeneration, this one is the 4th largest by enrollment of the 124 interventional ones that give a count, is one of 10 that started in 2014, is one of 33 in phase 4, and was the 83rd registered.
1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.
Browse Macular Degeneration studies →3 of the 125 studies testing ranibizumab in Macular Degeneration are open now, in 12 countries. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in Austria, Czechia, Denmark and 10 more countries
Ages 50+
AO GENERIUM · Sites in Russian Federation
Ages 50+
AbbVie · Sites in United States
By country, each count listing its studies:
Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 165 Macular Degeneration studies recruiting now, 116 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
125 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 43 · Phase 3 35 · Phase 4 33
First in 2002; this study’s year is marked. 10 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,049 is above the median of 56 across 985 interventional studies indexed under Macular Degeneration.
Median enrollment 64 across the 124 interventional studies. Of the 98 that completed or were terminated, 42 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
58 of 125 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
81 studies in Macular Degeneration by Novartis: 1 open now, 1 under way, none of them phase 3. Of 79 finished, 41 (52%) have results posted.
Among the 81 studies in Macular Degeneration by Novartis, this one has the largest enrollment of the 56 interventional ones that give a count, is one of 4 that started in 2014, is one of 18 in phase 4, and was the 31st registered.
Novartis’s Macular Degeneration studies by the year they started, since 2003.
3 of the studies testing ranibizumab in Macular Degeneration that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04657289Phase 3Hoffmann-La RocheA Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome) | 2027-02-04 |
| NCT05562947Phase 3Hoffmann-La RocheA Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD) | 2027-06-30 |
| NCT04853251Genentech, Inc.A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS) | 2027-07-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 125 studies testing ranibizumab in Macular Degeneration, from their registry updates:
Among Novartis’s 81 in Macular Degeneration:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and efficacy of ranibizumab in patients affected by wet age related macular degeneration (wAMD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Male or female patients aged 50 years or above Willing and capable to provide informed written consent Eye(s) eligible for ranibizumab treatment, with a BCVA below 2/10 due to wet AMD and/or Second eye eligible for ranibizumab treatment, with first eye treated (currently or previously) with ranibizumab, whichever BCVA. In bilateral wAMD patients, the second eye can be included only if the first eye has been treated at least 14 days before with ranibizumab
Exclusion Criteria:
Active intraocular inflammation (grade trace or above) in either eye Any ocular or periocular active infection (current or suspected), e.g. conjunctivitis, keratitis, scleritis, uveitis, endophtalmitis, in either eye Risk factors for retinal pigment epithelial tear (including pigment epithelial retinal detachment) Ocular disorders that may confound interpretation of results compromise visual acuity or require medical or surgical intervention during the study period including cataract, retinal vascular occlusion, retinal detachment or macular hole Uncontrolled glaucoma in either eye (IOP ≥ 30 mmHg on medication or according to investigator's judgment) History of vitrectomy in the study eye History of stroke or Systemic treatment with any VEGF inhibitor in the 90 days prior to study enrollment Ocular treatment of the study eye with any anti-angiogenic drugs within 1 month prior to study enrollment Any intraocular surgery in the study eye within 28 days prior to enrollment Women of UNLESS using effective during treatment Pregnant or lactating women Simultaneous participation in a study that includes administration of any drug Known to ranibizumab or any component of the ranibizumab formulation Inability to comply with study procedures.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Administered as an Intravitreal injection
Drug: ranibizumab
All patients will receive ranibizumab 0.5 mg/0.05 ml according to approved label: treatment is given monthly until maximum VA is achieved (i.e. stable VA for three consecutive monthly assessments performed while on ranibizumab treatment). Thereafter according to approved label, patients should be monitored monthly for visual acuity and treatment is to be resumed when monitoring indicates loss of visual acuity due to disease activity. Monthly injections should then be administered until stable visual acuity is reached again for three consecutive monthly assessments (implying a minimum of two injections).
Number of Participants With Systemic Drug-related Adverse Events
Monitoring and recording all adverse events, including serious adverse events.
Time frame: Baseline to Month 12
Number of Eyes With Ocular Drug-related Adverse Events
Monitoring and recording all adverse events, including serious adverse events.
Time frame: Baseline to Month 12
Overall Number of Ranibizumab Injections
Time frame: Baseline to month 12
Time Interval Between Injections in Bilateral Disease
Mean number of days between two consecutive injections per eye
Time frame: Baseline to month 12
Mean Number of Injections Per Patient
Number of injections per patient
Time frame: Baseline to month 12
Patients were recruited from investigative sites located in Italy.
| Milestone | Ranibizumab |
|---|---|
| Started | 936 |
| Completed | 774 |
| Not completed | 162 |
| Withdrew: Adverse event | 11 |
| Withdrew: Unsatisfactory therapeutic effect | 24 |
| Withdrew: Protocol violation | 4 |
| Withdrew: Withdrawal by subject | 76 |
| Withdrew: Lost to follow-up | 38 |
| Withdrew: Death | 9 |
Monitoring and recording all adverse events, including serious adverse events.
| participants | Ranibizumab |
|---|---|
| Serious Adverse Event | 3 |
| Non Serious Adverse Event | 0 |
| injections per patient | Ranibizumab |
|---|---|
| Overall Number of Ranibizumab Injections | 5.97 ± 3.62 |
Mean number of days between two consecutive injections per eye
| days | Ranibizumab |
|---|---|
| Time Interval Between Injections in Bilateral Disease | 51.94 ± 26.56 |
Number of injections per patient
| injections | Ranibizumab Overall | Unilaterally Treted | Bilaterally Treated |
|---|---|---|---|
| Mean Number of Injections Per Patient | 5.97 ± 3.62 | 5.35 ± 2.88 | 10.55 ± 4.98 |
Monitoring and recording all adverse events, including serious adverse events.
| eyes | Ranibizumab |
|---|---|
| Serious Adverse Event | 1 |
| Non Serious Adverse Event | 8 |
Collected over Adverse events are reported from time of first treatment until study exit (approximately 12 months). Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ranibizumab 0.5 mg | 9/936 (1%) | 63/936 (6.7%) | 76/936 (8.1%) |
| Event | Ranibizumab 0.5 mg |
|---|---|
| Femur fractureInjury, poisoning and procedural complications | 7/936 |
| PneumoniaInfections and infestations | 5/936 |
| Cardiac failureCardiac disorders | 3/936 |
| Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/936 |
| Transient ischaemic attackNervous system disorders | 3/936 |
| AnaemiaBlood and lymphatic system disorders | 2/936 |
| Atrial fibrillationCardiac disorders | 2/936 |
| Intestinal obstructionGastrointestinal disorders | 2/936 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 2/936 |
| Cognitive disorderNervous system disorders | 2/936 |
| Event | Ranibizumab 0.5 mg |
|---|---|
| Neovascular age-related macular degenerationEye disorders | 34/936 |
| InfluenzaInfections and infestations | 15/936 |
| Conjunctival haemorrhageEye disorders | 13/936 |
| CataractEye disorders | 10/936 |
| PyrexiaGeneral disorders | 10/936 |
All treated participants
| Age, Continuous(years) | Ranibizumab |
|---|---|
| Mean | 78.68 ± 7.34 |
| Age, Customized(Participants) | Ranibizumab |
|---|---|
| 18 to less than 65 years | 33 |
| 65 to 74 years | 212 |
| 75 to 84 years | 483 |
| 85 years and older | 208 |
| Sex: Female, Male(Participants) | Ranibizumab |
|---|---|
| Female | 582 |
| Male | 354 |
| Treatment by Eye(Participants) | Ranibizumab |
|---|---|
| Unilateral treatment | 823 |
| Bilateral treatment | 113 |
Showing the first 100 of 101 sites. Choose a country and city above to see the rest.
Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
No publications or documents are linked to this record.
Ran from Mar 2014 to primary completion in Jun 2016, 27 months.
Results were first posted in Jul 2019, 3 years 1 month after primary completion.
Of 24 industry-sponsored phase 4 interventional studies under Macular Degeneration, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 36. This study's 27 months is close to that.
Counting every sponsor, half of 45 studies reached it within 26 months; a quarter within 14 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ranibizumab